Charles River Laboratories International (CRL) Non-Current Debt (2009 - 2026)

Charles River Laboratories International has reported Non-Current Debt for 18 years, with the latest figure at $2.6 billion in Q2 2026.

• On a quarterly basis, Non-Current Debt rose 12.33% year-over-year to $2.6 billion in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 12.33% increase from a year earlier, with the FY2025 full-year figure at $2.1 billion, down 4.64% from the prior year.
• Non-Current Debt was $2.6 billion for Q2 2026 at Charles River Laboratories International, down from $2.7 billion in the prior quarter.
• The five-year high for Non-Current Debt was $3.0 billion in Q2 2022, with the low at $2.1 billion in Q4 2025.
• Average Non-Current Debt over 5 years is $2.6 billion, with a median of $2.6 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Non-Current Debt climbed 21.51% in 2022, then fell 15.37% in 2024.
• Over 5 years, Non-Current Debt stood at $2.7 billion in 2022, then declined by 2.23% to $2.6 billion in 2023, then retreated by 15.37% to $2.2 billion in 2024, then dropped by 4.64% to $2.1 billion in 2025, then climbed by 22.64% to $2.6 billion in 2026.
• The last three Non-Current Debt figures came in at $2.6 billion (Q2 2026), $2.7 billion (Q1 2026), and $2.1 billion (Q4 2025), per Business Quant data.